Actavis to Present at the 2007 UBS Global Generic and Specialty Pharmaceuticals Conference
Posted on: Monday, 30 April 2007, 09:00 CDT
CRANFORD, N.J., April 30 /PRNewswire/ -- Actavis will participate in the 2007 UBS Global Generic and Specialty Pharmaceuticals Conference on Tuesday, May 8th at 12:00 p.m. at the Grand Hyatt in New York City. Doug Boothe, Executive Vice President of U.S. Commercial and Administration, will be presenting at the conference.
A copy of the company's presentation will be available on the Investor Relations section of the Actavis Web site at http://www.actavis.us/.
About Actavis Group
Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. Based in Iceland, the company has operations in more than 30 countries, with over 11,000 employees. The Company's market cap is approximately EUR3.0bn (US$3.8 billion) and it's listed on the OMX Exhange in Iceland. For further information, visit http://www.actavis.com/
Actavis
CONTACT: Enquiries: Halldor Kristmannsson, VP of CorporateCommunications of Actavis, +354-535-2325, +354-840-3425,hkristmannsson@actavis.com
Web site: http://www.actavis.com/http://www.actavis.us/
Source: PRNewswire
Related Articles
- Actavis Totowa LLC Recalls Generic Drugs
- Glenmark Establishes New Company; Acquires Seven Brands in Poland
- Actavis Receives FDA Approval for Generic Cancer Drug
- FDA Gives Go Ahead for Actavis' Irinotecan Hydrochloride Injection
- Actavis Launches Generic Zoloft
- Actavis Launches Generic Glucotrol
- Alpharma Completes Sale of Global Generics Business to Actavis Group for $810 Million
- Alpharma Announces Sale of Global Generics Business to Actavis Group for $810 Million
- Actavis Acquires Keri Pharma Generics As Part of Its Expansion Strategy in the CEE Region
 |
 |
User Comments (0)
RSS Feeds